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ABSTRACT
Cancer-associated fibroblasts (CAFs) are believed to influence tumor behavior 
and clinical outcomes. We previously showed that conditioned medium (CM) from CAFs 
induces proliferation and motility of esophageal squamous cell carcinoma (ESCC) cells. 
Here, we investigated the molecular mechanisms by which the CAF-secreted proteins 
induce ESCC development and progression. Using antibody arrays, we identified 
urokinase plasminogen activator (uPA) as one of the main proteins whose release 
was increased in CAFs compared to normal fibroblasts (NFs). Immunohistochemical 
analysis of pathological sections showed that uPA-positive cells were localized at 
the boundaries of tumor and stroma tissues, in stroma between tumor nests, and 
within the tumors. Increased stromal uPA levels (132/146 cases) correlated with 
tumor invasion (p < 0.05) and overall survival of ESCC patients (p < 0.05). In vitro 
assays showed that uPA promotes ESCC cell proliferation, migration, and invasion via 
PI3K/AKT and ERK signaling pathways. In vivo, anti-uPA antibody suppressed tumor 
growth in ESCC xenografts. These results suggest that uPA released from stroma, and 
especially from CAFs, might be a predictive marker for ESCC diagnosis and prognosis, 
as well as an effective therapeutic target.
INTRODUCTION
Esophageal carcinoma (EC) is one of the most common 
cancers, with a poor prognosis. The major histological 
subtype of EC is esophageal squamous cell carcinoma 
(ESCC) [1]. The stroma of a carcinoma is the connective 
tissue below the basal lamina that directly surrounds the 
tumor cells [2]. Multiple components, including fibroblasts, 
extracellular matrix (ECM) and immune cells, form the 
cancer stroma [3, 4]. Cancer-associated fibroblasts (CAFs) 
are the activated form of fibroblasts in the tumor stroma 
[5] and are considered as the predominant cell type of the 
stroma [6]. Via paracrine manner, CAFs secrete a variety of 
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soluble factors that promote tumor growth and invasion [7], 
enhance angiogenesis [8], and activate endothelial cells and 
pericytes [6, 9].
Urokinase plasminogen activator (uPA) is a serine 
protease that converts plasminogen into the active serine 
protease plasmin. uPA mediates proteolysis of ECM 
by binding to a specific cell surface receptor, urokinase 
plasminogen activator surface receptor (uPAR) [10, 11]. uPA 
also participates in the initiation of epithelial–mesenchymal 
transition (EMT), angiogenesis, tumor invasion, and 
metastasis, as well as in signal transduction pathways [10, 
12]. Among breast cancer patients without lymph-node 
involvement, high levels of uPA correlate with poor prognosis. 
According to the American Society of Clinical Oncology, 
uPA may be a key factor in risk assessment and a possible 
treatment target [13, 14]. In clinics, a strong correlation has 
been found between cellular levels of uPA and aggressive 
behavior of ESCC [15–18]. However, the mechanism how 
uPA contributes to ESCC progression is unknown.
Our previous study has shown that CAFs induce a 
suitable microenvironment for ESCC development and 
progression compared with normal fibroblasts (NFs); 
however, the molecular mechanisms were unknown. In this 
study, an antibody array was used to identify the effectors 
released from ESCC-derived CAFs versus NFs that promote 
tumorigenesis. The results show that the high uPA expression 
is one of the major differences between CAFs and NFs. 
uPA derived from CAFs promotes ESCC cell proliferation, 
migration, and invasion in vitro. When uPA is blocked by 
anti-uPA antibody, the primary tumor growth is suppressed, 
and PI3K/AKT and ERK signaling pathways are deactivated. 
Immunohistochemistry analysis demonstrates a high uPA 
expression in ESSC stroma, including CAFs, had a reverse 
correlation between uPA levels and overall survival rates.
RESULTS
Expression of uPA is higher in CAFs than in NFs
Antibody array analysis of conditioned medium (CM) 
was performed from 4 pooled CAFs and their matched NFs, 
by using the RayBiotech L507 antibody array (Figure 1A). 
Compared with CM from NFs, 43 up-regulated proteins 
(8.48%) and 31 down-regulated proteins (6.11%) were 
detected in CM of CAFs using an arbitrary cutoff line of 
signal ratio of >1.50 or <-1.50 (Supplementary Table 1). 
Figure 1B shows the original normalization values of 
several candidate proteins. Compared to CM from NF 
controls, the uPA levels in CM from CAFs were more than 
two times higher. The uPA concentration in CAF CM was 
Figure 1: Expression of uPA is increased in ESCC CAFs. A. The fluorescent figures of antibody array. B. Representative images 
of original values of secreted proteins from CAFs and NFs. C. ELISA of secreted uPA in CAFs and NFs (n=6). D. qRT-PCR of uPA mRNA 
levels in CAFs and NFs (n=6). qRT-PCR data were normalized to the housekeeping gene β-actin. Experiments in C and D were done in 
triplicates. Error bars, mean ± SD.
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confirmed by ELISA; the average uPA concentration in 
CAF CM was 7.26 times higher than in NFs (Figure 1C). 
In addition, the uPA mRNA expression in CAFs was 
5.28 times higher than in NFs (Figure 1D).
uPA is expressed in primary ESCC tissues
To find out the distribution of uPA-positive 
cells in primary ESCC tissues, we performed 
immunohistochemistry (IHC) staining in a panel of tissue 
microarrays (TMAs) consisting of 300 matched pairs of 
primary ESCC and non-tumor specimens. Informative 
results of IHC staining of uPA were collected in 142 
primary ESCC cases. Non-informative samples, such as lost 
samples, samples with too few cells, and inappropriately 
stained samples, were not used as valid data. The uPA-
positive cells were located at the boundary between tumor 
and stroma tissues, in stroma between tumor nests, and 
within tumor tissues; however, uPA-positive cells were 
almost undetectable in adjacent non-tumorous esophageal 
tissues (Figure 2A). Our previous results have indicated 
that uPA is increased in fibroblast growth factor receptor 
2-positive cells, which is identified as CAFs, but not NFs 
[7]. We performed tissue double immunofluorescence 
using two-color (green vimentin; red uPA) staining and 
confirmed that uPA and vimentin were co-expressed in 
the same cells, suggesting that the uPA-positive cells were 
fibroblasts (Figure 2B). We then separated fibroblast cells 
from the primary tumors and their matched para-tumors, 
and performed immunocytochemistry. According to the 
immunocytochemistry results, uPA was expressed in 
cytoplasm of CAFs, but not in NFs (Figure 2C).
Figure 2: Distribution of uPA positive cells in primary ESCC tissues. A. Representative image of uPA-positive cells in human 
ESCC tissue and normal esophagus. In ESCC tissue, uPA-positive cells are frequently observed at the tumor/stroma boundary, in stroma 
between tumor nests, and within tumor tissue. The arrows indicate uPA-positive cells in tissues. Scale bar 100um. B. Representative images 
of CAFs labeled by antibodies against vimentin (green) and uPA (red). Nuclei were counterstained with DAPI (blue). Scale bar 200um. C. 
Immunocytochemistry with anti-uPA antibody for uPA expression in CAFs and NFs isolated from clinical samples. Vimentin was used as 
the fibroblast cell specific marker. Scale bar 100 um.
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uPA stroma expression correlates with ESCC 
invasion and poor prognosis
IHC analysis revealed that 90% (132/146) of primary 
ESCC cases were uPA-positive in ESCC stroma. The uPA 
stroma expression was associated with tumor invasion 
(Fisher’s exact test, P = 0.0393) (Table 1). Kaplan–Meier 
analysis was used to determine the survival curves of 
patients with uPA-positive and uPA-negative expression 
in stroma. The results showed that the overall survival was 
significantly shorter in patients with uPA-positive stroma 
expression (n = 132, median survival time 20 months) 
compared with patients with uPA-negative expression (n = 
14, median survival time 36 months) (Figure 3).
We have also investigated the uPA expression in 
tumor tissues of 146 informative ESCC cases. Our results 
showed no correlation between clinicopathologic features 
and patients with moderate and high uPA expression in 
tumor tissues (Table 1). Kaplan-Meier analysis of survival 
curves indicated that there was no statistical difference in the 
overall 5-year survival rates between patients with moderate/
high uPA tumor expression and patients with negative/low 
uPA tumor expression (Supplementary Figure 1). Together, 
these data indicate a reverse correlation between uPA stroma 
expression and ESCC prognosis.
uPA secreted by CAFs increases proliferation 
and migration of ESCC cells
The increased uPA mRNA and protein levels in 
CAFs compared to NFs suggested that the uPA released 
from CAFs might regulate ESCC cells via a paracrine 
manner. To analyze the effect of uPA on ESCC tumor 
progression, we treated ESCC cell lines EC109 and 
KYSE30 with uPA, or with CAF CM containing high 
levels of uPA (CAF4). Cells treated with 20 ng/ml of uPA 
or CAF CM had significantly accelerated growth rates 
than cells treated with DMEM control or NF CM. After 
neutralizing uPA with anti-uPA antibody, the proliferation 
rate decreased compared to cells treated with IgG control 
(Figure 4A). Moreover, when EC109 and KYSE30 
cells were treated with 20 ng/ml uPA or CAF CM, they 
exhibited increased migration and invasive potential 
compared to cells treated with DMEM or NF CM. 
Table 1: Association of uPA expression levels in ESCC stroma and tumor nest with clinicopathological features in 
146 clinical ESCC cases











Age ≥57 90 83 0.0450 0.8320 40 0.0138 0.9064
<57 56 49 24
Gender Female 66 58 0.0450 0.8321 32 0.4110 0.5215
Male 80 74 32
Depth of 
invasion
1 8 1 1
2 6 1 8.3520 0.0393* 2 1.8620 0.6016
3 32 32 14
4 100 98 47
T status T1–2 51 39 0.9186 0.3379 19 0.5506 0.4581
T3–4 95 93 45
LNM N0 78 69 0.0369 0.8476 34 0.0016 0.9680
N1 68 63 30
Clinical 
stage
I 6 1 1
II (a, b) 89 83 3.1747 0.2045 40 0.8960 0.6390
III–IV 51 48 23
*Statistical significance (p < 0.05) is shown in bold.
Oncotarget42304www.impactjournals.com/oncotarget
Furthermore, anti-uPA antibody co-incubation with uPA or 
CAF CM decreased the migration and invasive potential 
of these cells (Figure 4B, C).
uPA secreted by CAFs contributes to ESCC 
progression by activating PI3K/AKT and ERK 
signaling pathways
To investigate the uPA-mediated signaling in ESCC 
cells, we treated EC109 and KYSE30 cells with 20 ng/ml 
uPA, and analyzed the activity of PI3K, AKT, GSK3β, and 
ERK1/2. PI3K, AKT, GSK3β, and ERK1/2 were activated 
during 10–30 min (Supplementary Figure 2A–2D). To 
investigate whether uPA promotes ESCC progression via 
PI3K/AKT or ERK signaling pathways, we treated EC109 
and KYSE30 cells for 30 min with 10 μM LY294002, PI3K 
inhibitor, or U0126, MEK inhibitor, before uPA or CAF CM 
treatment. Our results show that uPA and CAF CM activate 
AKT, GSK3β, and ERK1/2. When uPA was neutralized 
with anti-uPA antibody, AKT, GSK3β, and ERK1/2 
phosphorylation levels were reduced. When LY294002 or 
U0126 was added, phosphorylation levels of AKT, GSK3β, 
and ERK1/2 were reduced; when both inhibitors were 
combined, their effects were cooperative (Figure 5A, 5B). In 
the in vitro function assays, we added 1 μM LY294002 and/or 
U0126 to inhibit PI3k/AKT and/or ERK signaling pathway 
before treating cells with uPA or CAF CM. Proliferation, 
migration, and invasion rates were significantly weakened in 
EC109 and KYSE30 cells activated with uPA or CAF CM 
(Figure 6). However, when EC109 or K30 cells were treated 
with 1 μM LY294002 or U0126 without uPA or CAF CM 
treatment, proliferation, migration, and invasion rates were 
not significantly changed (Supplementary Figure 3). These 
results indicate that the uPA-mediated ESCC progression 
depends on PI3K/AKT and ERK signaling pathways.
Inhibition of uPA suppresses tumor formation 
in vivo
To investigate the effects of uPA in vivo, we 
used nude mice implanted with KYSE30 cells. Mice 
bearing KYSE30 tumors (approximately 100 mm3) were 
randomized into two groups (n = 5). One group was 
treated with control IgG (0.3 mg/kg), and the other was 
treated with anti-uPA antibody (0.3 mg/kg), by intra-tumor 
injection every 3 days. After 4 weeks of therapy, the anti-
uPA antibody significantly decreased the tumor weight 
compared with the control IgG group (end-stage tumor 
weight: 0.1838 ± 0.06376 g in anti-uPA group versus 
0.4698 ± 0.05184 g in IgG control group) (Figure 7A, 
B). The tumor volumes were also significantly reduced 
in the group treated with anti-uPA antibody compared to 
the control IgG group (end-stage tumor volume: 488.5 ± 
64.36 mm3 in anti-uPA group versus 898.3 ± 21.15 mm3 
in IgG control group) (Figure 7C). Further histologic 
analysis revealed that anti-uPA antibody reduced tumor 
protein level of the proliferation marker Ki67, and 
phosphorylation levels of AKT and ERK (Figure 7D). 
Figure 3: Stroma uPA expression correlates with poor ESCC prognosis, determined by Kaplan–Meier analysis. Dotted 
line, patients with uPA-negative expression (n = 14, median survival 36 months); solid line, patients with uPA-positive expression (n = 132, 
median survival 20 months; *p<0.05, log-rank test).
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Figure 4: uPA secreted from CAFs functions as oncogenic protein during ESCC progression. A. Cell growth rates of EC109 
and KYSE30. Cells were seeded into 96-well plate at a density of 3×103 per well. After 6 h, cells were treated with either DMEM control 
or NF CM or 20 ng/ml uPA or CAF CM or 20 ng/ml uPA with 6 ug/ml IgG or CAF CM with 6 ug/ml IgG or 20 ng/ml uPA with 6 ug/ml 
anti-uPA antibody or CAF CM with 6 ug/ml anti-uPA antibodies. Cell growth rates were compared by WST-8 assays 48 h later. B. and C. 
Representative images of migratory and invasive cells per field with indicated treatment. Cells were seeded in the upper compartment at a 
density of 5×104 per chamber. After 6 h, cells were treated with either DMEM control or NF CM or 20 ng/ml uPA or CAF CM or 20 ng/ml 
uPA with 6 ug/ml IgG or CAF CM with 6 ug/ml IgG or 20 ng/ml uPA with 6 ug/ml anti-uPA antibody or CAF CM with 6 ug/ml anti-uPA 
antibodies. Migrated and invaded cells were counted after 36 h. Before the experiments, EC109 and KYSE30 cells were serum-starved for 
24 h, acid-washed to remove bound endogenous uPA, and then neutralized. CTL: DMEM control, u+IgG: uPA+IgG, uPA+A: uPA+Anti-
uPA antibody, NFs: NF CM, CAFs: CAF CM, C+IgG: CAF CM+IgG, C+A: CAF CM+Anti-uPA antibody. Experiments in A–C were 
repeated at least thrice. Error bars, mean ± SD. Scale bar 50 um.
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Quantitative analysis of Ki67, pAKT, and pERK staining 
is shown in Supplementary Figure 4. These results indicate 
that the uPA-mediated tumor growth can be arrested by 
blocking uPA.
DISCUSSION
Previous studies have indicated that CAFs stimulate 
tumor growth that provides suitable microenvironment 
for proliferation, angiogenesis, and invasion of ESCC 
via secreting various pro-oncogenic factors [6, 8, 19–
24]. Most up-regulated genes in CAFs have oncogenic 
functions, including growth factors FGF18 and HEBGF, 
transcription factors TFAP2A and TFAP2C, and the Wnt 
family members WISP1, WNT2, WNT5A, and LEF1. 
In this study, the antibody array analysis showed that in 
addition to uPA, CAFs also produce various growth factors 
and cytokines, such as the TGF-β superfamily (TGF-β3, 
Activin A, GDF8, and GDF11), VEGF, and interleukins 
IL-1 and IL-10 (Supplementary Table 1).
Expression of uPA by cancer cells or CAFs depends 
on the cancer type. uPA is expressed by cancer cells in 
skin squamous cell carcinoma, whereas in ovarian, 
breast and colon cancers, it is expressed mainly by 
fibroblasts [25, 26]. Pyke et al have shown that uPA is 
localized predominantly in CAFs at the invasive front 
of tumors in colon adenocarcinoma [27]. In the present 
study, our results show that CAFs release higher levels 
of uPA compared to NFs; this is in an agreement with our 
previous results demonstrating that the uPA mRNA levels 
are increased in CAFs compared to NFs. We demonstrate 
that the uPA-positive CAFs are present at the boundary 
of ESCC tumor and stroma, in the stroma between tumor 
nests, and within the tumor tissues (Figure 2A). The uPA 
ESCC stroma levels correlate with the tumor invasion, 
and negatively correlate with the overall survival rates. 
In contrast, there is no correlation between pathological 
features and expression levels of uPA in tumor tissues. 
However, even in the absence of uPA in tumor tissues, 
uPA could be still detected in the stroma samples. These 
findings suggest that it is the uPA expression in stroma, 
rather than in tumors, that is more directly related to tumor 
behavior in ESCC.
Previous studies have indicated that uPA activates 
ERK1 and ERK2 to promote migration of breast cancer 
cells [28]. In addition, uPA promotes migration of smooth 
muscle cells by activating PI3K, AKT/GSK3β, and ERK 
signaling pathways [29]. The down-regulation of uPA 
inhibits PI3K/AKT-dependent migration of glioblastoma 
cells [29, 30]. In the present study, in vitro analysis 
showed that uPA secreted from CAFs could induce ESCC 
proliferation, migration, and invasion, and these promotive 
functions were dependent on the PI3K/AKT and ERK 
signaling pathways. Targeting uPA by anti-uPA antibody 
could effectively neutralize uPA and subsequently 
deactivate the PI3K/AKT and ERK signaling pathways. 
Figure 5: uPA activates PI3K/AKT and ERK signaling pathways in ESCC cells. A. and B. EC109 and KYSE30 cells were 
incubated in the absence (-) or presence (+) of either DMEM control or NF CM or 20 ng/ml uPA or CAF CM or 20 ng/ml uPA with 6 ug/ml 
IgG or CAF CM with 6 ug/ml IgG or 20 ng/ml uPA with 6 ug/ml anti-uPA antibody or CAF CM with 6 ug/ml anti-uPA antibody or 20 ng/
ml uPA with 10um LY294002 or CAF CM with 10um LY294002 or 20 ng/ml uPA with 10um U0126 or CAF CM with 10um U0126 or 20 
ng/ml uPA with 10um LY294002 and 10um U0126 or CAF CM with 10um LY294002 and 10um U0126 for 20 min to assess activation of 
AKT, GSK-3β, and ERK. In the presence of LY294002 or U0126, cells were pretreated with these inhibitors for 30min. Cell lysates were 
immunoblotted with anti-phospho- and anti-total-antibodies to AKT, GSK-3β, and ERK. β-actin was used as a loading control. Before all 
of these experiments, EC109 and KYSE30 cells were serum-starved for 24 h, acid-washed to remove bound endogenous uPA, and then 
neutralized. Experiments in A, B were repeated at least thrice.
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Figure 6: uPA-mediated ESCC progression depends on PI3K/AKT and ERK signaling pathways. A. Cell growth rates of 
EC109 and KYSE30. Cells were seeded into 96-well plate at a density of 3×103 per well. After 6 h, cells were treated with 20 ng/ml uPA or 
CAF CM or 20 ng/ml uPA with 1um LY294002 or CAF CM with 1um LY294002 or 20 ng/ml uPA with 1um U0126 or CAF CM with 1um 
U0126 or 20 ng/ml uPA with 1um LY294002 and 1um U0126 or CAF CM with 1um LY294002 and 1um U0126. Cell growth rates were 
compared by WST-8 assays 48 h later. B. and C. Representative images of migratory and invasive cells per field with indicated treatment. 
Cells were seeded in the upper compartment at a density of 5×104 per chamber. After 6 h later, cells were treated with 20 ng/ml uPA or CAF 
CM or 20 ng/ml uPA with 1um LY294002 or CAF CM with 1um LY294002 or 20 ng/ml uPA with 1um U0126 or CAF CM with 1um U0126 
or 20 ng/ml uPA with 1um LY294002 and 1um U0126 or CAF CM with 1um LY294002 and 1um U0126. Migrated and invaded cells were 
counted after 36 h. Before all of these experiments, EC109 and KYSE30 cells were serum-starved for 24 h, acid-washed to remove bound 
endogenous uPA, and then neutralized. u+LY: uPA+LY294002, u+U: uPA+U0126, u+LY+U: uPA+LY294002+U0126, CAFs: CAF CM, 
C+LY: CAF CM+LY294002, C+U: CAF CM+U0126, C+LY+U: CAF CM+LY294002+U0126. Experiments in A–C were repeated at least 
thrice. Error bars, mean ± SD. Scale bar 50 um.
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These findings provide mechanism of uPA function in 
ESCC.
The prognosis of ESCC patients is poor and the 
overall 5-year survival rates range between 15% and 25%. 
At the time of diagnosis, ESCC is often metastasized to the 
lymph nodes and distant organs. Therefore, establishing 
effective detection and treatment strategies for ESCC 
is essential to improve ESCC diagnosis and prognosis. 
Our results suggest that uPA secreted from the stroma, 
especially CAFs, might be used as a predictive marker 
for ESCC diagnosis and prognosis as well as an effective 
therapeutic target.
Figure 7: Inhibition of uPA with anti-uPA antibody suppresses tumor formation in vivo. A. Tumor weights in nude mice 
were compared between mice treated with anti-uPA antibody and control IgG. Error bars mean ± SD. B. Representative images of tumors 
formed in nude mice following injection with anti-uPA antibody or IgG control. Scale bar 1 cm. C. Tumor growth curves in nude mice in 
the two treatment groups. Error bars, mean ± SD. D. Representative IHC images of Ki67, p-AKT, and p-ERK in mice treated with anti-uPA 




CAFs and their matched NFs were isolated from 
primary ESCC as described previously [31]. Cells were 
maintained in DMEM medium supplemented with 20% 
fetal bovine serum (FBS), 100 units/mL penicillin, and 
10 mg/mL streptomycin. A total of 26 pairs of ESCC 
specimens and their matched non-tumor tissues were 
provided by Guangzhou Medical University Cancer 
Institute and Hospital (Guangzhou, China). None of 
the patients received preoperative chemotherapy and 
radiotherapy. The study proposal was reviewed by Human 
Subject Research Ethics Committee of Cancer Center 
of Guangzhou Medical University, and was performed 
according to the guidelines set forth by this committee.
Cell lines and reagents
Chinese ESCC cell line EC109 was kindly 
provided by Professor Tsao (Department of Anatomy, 
The University of Hong Kong). Japanese ESCC cell 
line KYSE30 was acquired from DSMZ (Braunschweig, 
Germany), the German Resource Centre for Biological 
Material. The cell authenticities were tested by short 
tandem repeat analysis technology. Cells were maintained 
in DMEM medium supplemented with 10% FBS, 
100 units/mL penicillin, and 10 mg/mL streptomycin. 
Recombinant uPA protein was bought from Sino 
Biological Inc. LY294002 and U0126 were obtained from 
Selleck Chemicals. IgG was purchased from R&D system.
Preparation of conditioned medium (CM)
CAFs and their matched NFs were seeded into 
6-well plates at a density of 2 × 106 per well and grown 
in serum-free DMEM for 48 h. Culture medium was then 
collected from each well and centrifuged at 2,000 g for 
5 min. The supernatant was collected as conditioned 
medium (CM) for antibody array and further studies.
Antibody array
Antibody array (human L507 array, glass slide, 
RayBiotech) was performed according to manufacturer’s 
protocol. Samples were biotin-labeled and stored at -80 °C 
before the assay. A glass chip was placed in laminar flow 
hood to dry for 1–2 h. Blocking-buffer was added into each 
well and incubated at room temperature (RT) for 30 min. 
Equal volumes of biotin-labeled CM samples from four CAFs 
(or their paired NFs) were pooled together, and 400 µL of 
diluted samples was added into wells. Arrays were incubated 
with gentle shaking overnight at 4 °C and then washed 
briefly; 400 µL of Cy3-conjugated streptavidin was added to 
each sub-array and incubated at RT for 2 h. The slides were 
subsequently washed and dried completely before scanning. 
The data were analyzed with RayBio Analysis Tool software.
Quantitative real-time PCR
Total RNA was isolated using RNAiso Plus 
(Takara) according to manufacturer’s protocol. First-
strand cDNA was synthesized using a first-strand 
reverse transcription kit (Takara), and qRT-PCR 
reaction was performed on CFX96 Touch™ Real-
Time PCR Detection System with SYBR Green 
Dye mix (TaKaRa). Primer sequences for qRT-PCR 
were as follows: β-actin 5′-GCTTGTCCAAGAGT 
GCATGGT-3′ and 5′-CAGGGCTGGTTCTCGATGG-3′; 
uPA 5′-CCTGGCACCCAGCACAAT-3′ and 
5′-GGGCCGGACTCGTCATAC-3′. Amplification 
parameters were as follows: 40 cycles of 94 °C for 15 
s, 60 °C for 15 s, and 72 °C for 15 s. The results were 
normalized to β-actin, and calculation was done by 
comparative CT method (ΔΔ CT method).
Sandwich ELISA
ELISA was performed using the ELISA kit for uPA 
(Cloud-Clone Corp). Briefly, 100 µL of diluted CM was 
added to each well and incubated for 2 h at 37 °C. CM 
was then aspirated, and detection antibody was added and 
incubated for 1 h at 37 °C. Wells were washed, incubated 
with HRP-linked secondary antibody for 30 min at 37 °C, 
and developed with 3, 3’, 5, and 5’-tetramethylbenzidine.
ESCC tissue microarray and 
immunohistochemistry (IHC) staining
A panel of 300 formalin-fixed, paraffin-embedded 
ESCC tumors and their paired non-tumor specimens 
was obtained from Linzhou Cancer Hospital. The 
clinicopathological summaries were collected between 
2001 and 2005.
The ESCC tissue microarray (TMA) was constructed 
as previously described [32]. For IHC analysis, all slides 
were deparaffinized and rehydrated, and endogenous 
peroxidase activity was blocked with 3% hydrogen 
peroxide for 20 min. Antigen retrieval was performed by 
heating the slides in a microwave oven for 10 min in 10 
mmol/L sodium citrate buffer (pH 6.0). The slides were 
then incubated with goat anti-human uPA polyclonal 
antibody (R&D system) at 4 °C overnight. Subsequently, 
the slides were incubated with biotinylated donkey 
anti-goat immunoglobulin for 30 min at 37 °C. Isotope-
matched human IgG was used in each case as a negative 
control. Finally, the 3, 30-diaminobenzidine (DAB) 
substrate Kit (Dako Ltd.) was used for color development 
followed by Mayer’s hematoxylin counterstaining.
The uPA immunoreactivities of the tumor nests and 
stroma were assessed separately. When five or more uPA 
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positive cells were observed in a 200× microscopy field, 
it was defined as uPA-positive in ESCC stroma. Scoring 
of uPA in tumor tissues was performed as follows: (a) 
proportion of positively stained cells (0, <5%; 1, 6%–
25%; 2, 26%–50%; 3, 51%–75%; 4, >75%) and (b) the 
intensity of staining (0, negative staining; 1, mild staining; 
2, moderate staining; 3, strong staining). Scores were 
measured as a × b; 0 points were defined as negative, 1–3 
points were defined as weakly positive, 4–7 points were 
defined as moderately positive, and 8–12 points were 
defined as strongly positive. Upon analysis, 0–3 points 
were considered as uPA-negative and low expression 
level, and 4–12 points were considered as moderate and 
high expression level. None of the patients received 
preoperative chemotherapy and radiotherapy. All clinical 
samples used in our investigation were approved by the 
committees for ethical review of research involving human 
subjects at Zhengzhou University (Zhengzhou, China) and 
Jinan University.
IHC of mice tumor tissues was performed according 
to published methods [33]. Ki67 (Sigma-Aldrich), p-AKT 
and p-ERK (Cell Signaling Technology) positive cells 
were counted at five arbitrarily selected fields from each 
tumor at 200x magnification.
Immunocytochemistry
For immunocytochemistry, CAFs and NFs were 
seeded into a 96-well plate and cultured in DMEM 
medium with 10% FBS until 80% confluence. Cells were 
fixed with 4% paraformaldehyde for 20 min, and the 
endogenous peroxidase activity was blocked. Antigen 
retrieval, antibody incubation, and color development 
were performed as described in the IHC protocol. Mouse 
antibody against vimentin was purchased from BD 
Pharmingen.
Cell proliferation assay
EC109 and KYSE30 cells were starved for 24 h 
with serum-free DMEM medium, acid-washed (50 mM 
glycine-HCl, 100 mM NaCl, pH 3.0) for 3 min to remove 
bound endogenous uPA, and then neutralized (0.5 M 
HEPES, 0.1 M NaCl, pH 7.5) for 10 min. The effect of 
uPA on cell proliferation was evaluated by seeding 3×103 
cells per well in 96-well plates. After 6 h, cells were 
treated with 20 ng/ml uPA or CM for 48 h. Proliferation 
rate was determined by WST-8 2-(2-methoxy- 
4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-
2H-(tetrazolium) assay using a cell counting kit-
8 (Dojindo Molecular Technologies) according to 
manufacturer’s protocol. Three independent experiments 
were conducted.
Immunofluorescence
For double-labeling immunofluorescence, paraffin 
block sections of ESCC were incubated with a mouse 
antibody against vimentin and a goat antibody against 
uPA simultaneously at 4 °C overnight. After brief 
washing, slides were incubated with Alexa Fluor 594 
conjugated donkey anti-goat (Invitrogen) and Alexa 
Fluor 488 conjugated donkey anti-mouse (Invitrogen) 
secondary antibodies at RT for 1 h. After brief washing, 
slides were counterstained with DAPI in anti-fade 
solution.
Cell migration and invasion assays
In migration and invasion assays, EC109 
and KYSE30 cells were starved, acid-washed, and 
neutralized as described above. In addition, 5×104 
cells were suspended in serum-free medium DMEM 
and plated in the upper compartment of each chamber 
(BD Biosciences). For invasion assay, the upper 
compartments of the chamber were coated with matrigel. 
The lower compartments were filled with 20% FBS 
DMEM. After 6 h, cells were treated, and after 36 h of 
incubation, plates were fixed, stained, and counted under 
a microscope. Three independent experiments were 
performed in triplicates.
Western blot analysis
Western blot analysis was performed as previously 
described [34]. Densitometry was performed using 
Quantity One analysis software (Bio-Rad Laboratories). 
Three independent experiments were performed. The 
following antibodies were used: β-actin (Sigma-Aldrich), 
PI3K, AKT, GSK3β, ERK, phospho-PI3K, phospho-AKT, 
phospho-GSK3β, and phospho-ERK (Cell Signaling 
Technology).
In vivo mouse model
The in vivo function of uPA was investigated 
by tumor xenograft experiment. Approximately 2×106 
KYSE30 cells were injected subcutaneously into the 
right hind legs of 4-week-old nude mice. When tumors 
grew up to 100 mm3, mice were randomized into anti-uPA 
antibody (0.3 mg/kg) and control IgG (0.3 mg/kg) groups. 
Antibodies were injected intra-tumor every 3 days. Tumor 
growth in nude mice was monitored over a 4-week period. 
The tumor volume was calculated by the formula V = 
0.5 × L × W2 [35]. Animal experiments were performed 
in compliance with the guidelines for the Welfare of 
Experimental Animals in Sun Yat-Sen University.
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Statistical analysis
Statistical analysis was performed using SPSS19.0 
and GraphPad Prism 5 software. Data are expressed as 
mean ± SD from at least three independent experiments. 
Significance was analyzed by Student’s t-test (two-
tailed). The correlation between uPA expression and 
clinicopathologic characteristics was analyzed using 
Fisher’s exact test. Survival curves were assessed by the 
Kaplan–Meier method and compared by the log-rank test. 
Differences were considered significant at p<0.05.*, p 
<0.05; **, p < 0.01; ***, p <0.001.
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